Longeveron (NASDAQ:LGVN) PT Lowered to $6.00 at Maxim Group

Longeveron (NASDAQ:LGVN) had its target price reduced by Maxim Group from $15.00 to $6.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock.

Separately, HC Wainwright reissued a buy rating and set a $10.00 target price on shares of Longeveron in a research note on Thursday, August 15th.

Longeveron Stock Performance

Shares of NASDAQ LGVN opened at $2.09 on Tuesday. Longeveron has a 1 year low of $0.77 and a 1 year high of $35.60. The company’s fifty day moving average price is $2.67 and its 200 day moving average price is $2.80. The company has a market capitalization of $13.27 million, a PE ratio of -0.22 and a beta of 0.43.

Institutional Investors Weigh In On Longeveron

An institutional investor recently bought a new position in Longeveron stock. Renaissance Technologies LLC bought a new stake in Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 146,700 shares of the company’s stock, valued at approximately $236,000. Renaissance Technologies LLC owned 2.31% of Longeveron as of its most recent SEC filing. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.